You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

June 29, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

5 drug categories having the biggest impact on pharma spending

The transformations taking place throughout all healthcare sectors will have repercussions for the pharmaceutical industry. How will they affect industry prospects, and what are the implications for drug manufacturers? » Know the cost-driving drug categories

4 ways the FAST Generics Act will help healthcare

Rep. Steve Stivers (R-Ohio) and Rep. Peter Welch (D-Vt.) have re-introduced the Fair Access for Safe and Timely (FAST) Generics Act to what they say will increase consumer access to generic drugs, boost market competition and ultimately save consumers money. » Get the details

Continuing Education

MTM essentials for COPD management: Part 1

This month’s CE activity is part of a CPE series, Medication Therapy Management for the Patient with Respiratory Disease. From April 2015 through December 2015, pharmacists can earn up to 18 hours of CPE credit with 9 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month’s activity is to assist pharmacists in understanding the pathophysiology and pharmacologic treatment of COPD and to discuss how COPD is similar to and different from other chronic respiratory disorders.

To read and print the article with TEST QUESTIONS, click here.

To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT31-KTJ28.


Announcement: The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. To review your registration page or to register, go to: https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

FDA OKs antiplatelet for use during heart procedure

FDA has approved cangrelor (Kengreal, The Medicines Company) for reducing the risk of periprocedural thrombotic events in patients undergoing percutaneous coronary intervention. » Read more

 

RELATED ARTICLES

The 5 most over-prescribed antibiotics

HSCA to FDA: Address backlog of generic drug applications

RESOURCES

Latest Clinical News

Powered by Modern Medicine UBM  logo

UBM MEDICA